Ebola virus vaccine - Merck/MSD Wellcome Trust Hilleman Laboratories
Alternative Names: Research programme: Second generation Zaire Ebolavirus Vaccine - Hilleman LaboratoriesLatest Information Update: 12 Jul 2023
At a glance
- Originator Merck & Co; MSD Wellcome Trust Hilleman Laboratories
- Class Synthetic vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Ebola virus infections